| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:2393.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Protects the Heart From Ischemia/Reperfusion Injury
From GlaxoSmithKline Pharmaceuticals, King of Prussia, Pa.
Correspondence to Tian-li Yue, PhD, Cardiovascular Pharmacology, GSK, 709 Swedeland Rd, King of Prussia, PA 19406. E-mail tian-li_yue{at}gsk.com
Received August 28, 2002; de novo received April 9, 2003; revision received July 9, 2003; accepted July 11, 2003.
Background Peroxisome proliferatoractivated receptor-
(PPAR-
) is expressed in the heart and regulates genes involved in myocardial fatty acid oxidation (FAO). The role of PPAR-
in acute ischemia/reperfusion myocardial injury remains unclear.
Methods and Results The coronary arteries of male mice were ligated for 30 minutes. After reperfusion for 24 hours, ischemic and infarct sizes were determined. A highly selective and potent PPAR-
agonist, GW7647, was administered by mouth for 2 days, and the third dose was given 1 hour before ischemia. GW7647 at 1 and 3 mg · kg-1 · d-1 reduced infarct size by 28% and 35%, respectively (P<0.01), and myocardial contractile dysfunction was also improved. Cardioprotection by GW7647 was completely abolished in PPAR-
null mice. Ischemia/reperfusion downregulated mRNA expression of cardiac PPAR-
and FAO enzyme genes, decreased myocardial FAO enzyme activity and in vivo cardiac fat oxidation, and increased serum levels of free fatty acids. All of these changes were reversed by GW7647. Moreover, GW7647 attenuated ischemia/reperfusion-induced release of multiple proinflammatory cytokines and inhibited neutrophil accumulation and myocardial expression of matrix metalloproteinases-9 and -2. Furthermore, GW7647 inhibited nuclear factor-
B activation in the heart, accompanied by enhanced levels of inhibitor-
B
.
Conclusions Activation of PPAR-
protected the heart from reperfusion injury. This cardioprotection might be mediated through metabolic and antiinflammatory mechanisms. This novel effect of the PPAR-
agonist could provide an added benefit to patients treated with PPAR-
activators for dyslipidemia.
Key Words: receptors ischemia reperfusion myocardial infarction
This article has been cited by other articles:
![]() |
J. R. Ussher and G. D. Lopaschuk The malonyl CoA axis as a potential target for treating ischaemic heart disease Cardiovasc Res, July 15, 2008; 79(2): 259 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-L. Yue, S. S. Nerurkar, W. Bao, B. M. Jucker, L. Sarov-Blat, K. Steplewski, E. H. Ohlstein, and R. N. Willette In Vivo Activation of Peroxisome Proliferator-Activated Receptor-{delta} Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 466 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Jucker, D. Yang, W. M. Casey, A. R. Olzinski, C. Williams, S. C. Lenhard, J. J. Legos, C. T. Hawk, S. K. Sarkar, and S. J. Newsholme Selective PPAR{delta} agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1256 - E1264. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload Hypertension, May 1, 2007; 49(5): 1084 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Finck The PPAR regulatory system in cardiac physiology and disease Cardiovasc Res, January 15, 2007; 73(2): 269 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Y. Ng, C. Morisseau, J. R. Falck, B. D. Hammock, and D. L. Kroetz Inhibition of Smooth Muscle Proliferation by Urea-Based Alkanoic Acids via Peroxisome Proliferator-Activated Receptor {alpha}-Dependent Repression of Cyclin D1 Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2462 - 2468. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Gilde, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. van der Vusse and M. van Bilsen Free Fatty Acids and Postischemic Myocardial Function. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 231 - 235. [Abstract] [PDF] |
||||
![]() |
T. G. Neilan, G. A. Doherty, G. Chen, C. Deflandre, H. McAllister, R. K. Butler, S. E. McClelland, E. Kay, L. R. Ballou, and D. J. Fitzgerald Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H532 - H536. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Asai, K. Okumura, R. Takahashi, H. Matsui, Y. Numaguchi, H. Murakami, R. Murakami, and T. Murohara Combined therapy with PPAR{alpha} agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency Cardiovasc Res, June 1, 2006; 70(3): 566 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamaguchi, S. Matsushita, K. Motojima, F. Hirose, and T. Osumi MLDP, a Novel PAT Family Protein Localized to Lipid Droplets and Enriched in the Heart, Is Regulated by Peroxisome Proliferator-activated Receptor {alpha} J. Biol. Chem., May 19, 2006; 281(20): 14232 - 14240. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. G. Neilan, D. S. Jassal, M. F. Scully, G. Chen, C. Deflandre, H. McAllister, E. Kay, S. C. Austin, E. F. Halpern, J. H. Harmey, et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression Eur. Heart J., May 2, 2006; 27(10): 1251 - 1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 977 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, L. Lu, C. Greyson, M. Rizeq, K. Nunley, B. Wyatt, M. R. Bristow, C. S. Long, and G. G. Schwartz The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1798 - H1807. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk Chronic activation of PPAR{alpha} is detrimental to cardiac recovery after ischemia Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H87 - H95. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z Yuan, Y Liu, Y Liu, J Zhang, C Kishimoto, Y Wang, A Ma, and Z Liu Cardioprotective effects of peroxisome proliferator activated receptor {gamma} activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor {kappa}B blockade Heart, September 1, 2005; 91(9): 1203 - 1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Crozier, T. C. Vary, S. R. Kimball, and L. S. Jefferson Cellular energy status modulates translational control mechanisms in ischemic-reperfused rat hearts Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1242 - H1250. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Dewald, S. Sharma, J. Adrogue, R. Salazar, G. D. Duerr, J. D. Crapo, M. L. Entman, and H. Taegtmeyer Downregulation of Peroxisome Proliferator-Activated Receptor-{alpha} Gene Expression in a Mouse Model of Ischemic Cardiomyopathy Is Dependent on Reactive Oxygen Species and Prevents Lipotoxicity Circulation, July 19, 2005; 112(3): 407 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |